Category: Cancer Research

A Brilliant Scientist of Biogerontology; Mikhail Blagosklonny

Published / by CapaConf

Mikhail Blagosklonny has been in the field of oncology for more than 18 years. He is basically a scientist from Russia but currently, lives in the US.Dr. Mikhail Blagosklonny started the research study at the Roswell Park Cancer Institute almost five years ago. This cancer institute is situated in New York. Before this research, Mikhail Blagosklonny was a professor at the New York Medical College. He used to teach Medicine. In the year 2009, Mr. Blagosklonny was offered a position in this College of becoming a professor of oncology. After leaving the New York Medical College, Mr. Mikhail Blagosklonny became a member of the Ordway Research Institute. This is also a New York based institute. He became a senior scientist in the year 2002 and worked till 2009. All these years he wanted to join an institute where he could have freedom for his study and research in his field. His interests were in the field of aging and oncology.

Dr. Mikhail Blagosklonny studied at the First Pavlov State Medical University in St. Petersburg. His subject was internal medicine. He has a Ph.D. as well in experimental medicine. From the very start, he was among the best in some of the best institutes in the country.During his career, Dr. Mikhail Blagosklonny always supported the drug Rapamycin which was created as an anti-aging drug. This drug uses TOR signaling and is basically a cure for cancer. Dr. Mikhail Blagosklonny has always been very obsessive about medicines.Dr. Mikhail Blagosklonny is considered one of the best scientific researcher but its, not the only field he has worked in. He works as a chief editor as well. Dr. Mikhail Blagosklonny is an editor of Aging and Cell Cycle, two journals related to the field of aging and biogerontology. In addition to all that, Dr. Mikhail Blagosklonny is a Chief Editor of Oncotarget as well. Oncotarget has published papers on Oncology and several other subjects as well.

Dr. Mikhail Blagosklonny serves as an associate editor of Cancer Biology and Therapy, one of the best journals on this topic. He is a member of a board for several other similar journals as well.Dr. Mikhail Blagosklonny has written a lot of research papers in his career. He has documented all of his research. There are more than 200 articles written by Dr. Mikhail Blagosklonny. More than half of them have been published in different journals as well.Dr. Mikhail Blagosklonny has been studying the field of Oncology for many years now. He has researched quite a lot of useful information about aging and Oncology. His main point of interest has been the death of cells. Dr. Mikhail Blagosklonny has been working very hard on finding a way to reduce the number of deaths of cells. The study of Biogerontology is related to the aging process in a body. Dr. Mikhail Blagosklonny has done a lot of research, experimentations and taken tests to find a groundbreaking way of decreasing the decay of cells in a human body.

Eric Lefkofsky sees cancer going out with a whimper

Published / by CapaConf

Over the course of the last 100 years, many diseases have seen spectacular resolutions to their reign of death over humanity. Such diseases as polio, malaria and smallpox have all but been fully eradicated from the first world. Many of these diseases owe their demise to the individual genius of men like Jonas Salk, who single-handedly devised 100 percent effective cures for ailments that once caused untold suffering and death.

However, in more recent years, many other diseases have not so much been cured as they have become permanently manageable. This is the case with some forms of cancer, as well as diseases like syphilis and hepatitis C, which, in times past, had been major causes of mortality.

Eric Lefkofsky is a somewhat unlikely figure to jump headlong into the race towards the eradication of cancer. As the famous co-founder of group discount firm Groupon, he has gone on to have a superlative career as an entrepreneur, founding nearly a dozen startups and becoming one of the most noted philanthropists in the state of Illinois.

But things took a fateful turn for Lefkofsky when, in 2103, his wife was diagnosed with late-stage breast cancer. He was perturbed to discover that the oncologists seeing his wife routinely had less useful data at their disposal than what the built-in client interface on Groupon divulges to its rank-and-file customers. He decided to research ways in which oncologists could be provided more useful data with more actionable intelligence. This led to the startup firm Tempus.

Tempus is dedicated to centralizing the reams of data that could potentially be relevant to oncologists, putting it all into one place. But the most promising source of data is the human genome itself. Lefkofsky believes that with the cheap sequencing of entire individual human genomes, the way in which cancer is treated will radically change in the coming decade.

Lefkofsky sees cancer, over the next 10 to 30 years, going the way of diseases like AIDS. Patients may not be cured of the disease, in the technical sense, but they will be able to live with many forms of cancer practically indefinitely. Even diseases like pancreatic cancer may see survival rates approaching that of disease-free populations.

Learn More: www.tempus.com/about-us/

Seattle Genetics and Its Contributions to the Treatment of Cancer

Published / by CapaConf / 1 Comment on Seattle Genetics and Its Contributions to the Treatment of Cancer

The Bothell-based Biotechnology Company; Seattle Genetics is focused on innovative empowered monoclonal antibody-based therapies to aid in the treatment of cancer. The company is a global leader in the development of antibody-drug conjugates (ADCs), an innovation that assists in harnessing the targeting capability of antibodies to direct cell-killing agents to cancer cells. ADCs are designed to single out non-targeting cells, thereby reducing the adverse toxic effects of traditional chemotherapy. This procedure has the potential to improve antitumor activity.

ADCETRIS (Brentuximab Vedotin), which is the company’s main product, is commercially available in over 60 nations including European Union, Canada, U.S., and Japan. The availability of ADCETRIS in these countries has been made possible with the collaboration between Seattle Genetics and Takeda Pharmaceutical Company Limited. Seattle Genetics has exclusive rights to market Brentuximab vedotin in the United States and Canada while Takeda Pharmaceutical has the rights to market the product in the remaining nations.

The CD30-targeted ADC is being tested broadly in many ongoing clinical trials. These trials will serve as a basis to evaluate the product’s therapeutic potential. Apart from Brentuximab vedotin, Seattle Genetics is also working to improve vadastuximab Talirine (SGN-CD33A; 33A). Vadastuximab Talirine is expected to proceed to the third phase for acute myeloid leukemia later this year. The company is also working on a broad pipeline of products, including Enfortumab Vedotin, SEA-CD40, SGN-CD19B, SGN-CD70A,(Denintuzumab Mafodotin), SGN-CD19A; 19A, ASG-15ME, ASG-22ME, and SGN-LIV1A.

These products are a result of collaborations between Seattle Genetics and different biotechnology companies including GlaxoSmithKline, AbbVie, Bayer, Pfizer and Genentech

The President of Seattle Genetics: Clay B. Siegall

Clay B. Siegall is the co-founder of Seattle Genetics. He founded the company in 1998. Currently, he is serving as the company’s Chief Executive Officer, President, as well as Chairman of the Board. The company was established on a foundation of detailed research, scientific innovation, drug development practices and of course a passion for assisting cancer patients.

Mr. Siegall has steered the company to its present position. It is under his leadership that the company’s first ADC product, ADCETRIS (Brentuximab Vedotin) was approved. Brentuximab Vedotin is now a global brand being commercialized in over 60 nations. It is also during his tenure that the company has entered into different strategic licenses for its ADC innovation. Mr. Siegall is also a renowned author who has over 70 publications. On top of that, he holds over 10 patents.

Original Sources:

http://seekingalpha.com/article/3991804-seattle-genetics-sgen-clay-b-siegall-q2-2016-results-earnings-call-transcript